PPLPHARMA · Healthcare
Piramal Pharma Ltd. reported revenue of ₹1,951 cr for April to June 2024, +11.6% on the year and −23.6% on the quarter.
Operating profit (EBITDA) was ₹204 cr, a margin of 10.5%, +293 bps on the year and −1,028 bps on the quarter. Operating costs grew +8.0% against revenue growth of +11.6%, so more of each rupee of sales reached operating profit.
The net loss was ₹88.6 cr, with earnings per share of −₹0.67.
On earnings per share of ₹0.22 over the last four quarters, the stock at ₹197.46 trades at 897.5 times trailing earnings.
Written from the quarterly statements. The filing read adds the balance sheet and cash flow, the auditor's review, segment results, one-off items line by line and what management said on the call.
No check fired. That is a statement about the checks below, not a verdict on the company.
Could not run on this quarter: Headline vs core profit, Other income carrying profit, Exceptional items that recur, Cash behind the profit, Receivables against sales, Inventory against sales, Borrowing while holding cash, Auditor's review or audit report, IPO money used as stated, Related-party transactions, Exits, postponements, restatements, Promoter pledges and allotments, Earlier promises against delivery, When the results were filed. Most need the filing read (balance sheet, cash flow, auditor, disclosures).
Net profit a year ago, each driver's change, and net profit now. Blue added profit, red took it away.
| Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,959 cr | ₹2,552 cr | ₹1,951 cr | ₹2,242 cr | ₹2,204 cr | ₹2,754 cr | ₹1,934 cr | ₹2,044 cr | ₹2,140 cr | ₹2,752 cr | ₹2,270 cr | ₹2,617 cr |
| YoY | — | — | +12% | +17% | +13% | +8% | −1% | −9% | −3% | −0% | +17% | +28% |
| EBITDA margin | 13.7% | 20.8% | 10.5% | 15.2% | 15.3% | 20.4% | 5.5% | 7.8% | 9.1% | 16.7% | 8.6% | 13.3% |
| Other income, % of PBT | 223% | 3% | — | 65% | 44% | 21% | — | — | — | −270% | — | 66% |
| Exceptional items | — | — | — | — | — | — | — | — | — | — | — | — |
| Tax rate | 48% | 55% | — | — | — | 44% | — | — | — | — | — | — |
| Net profit | ₹10.1 cr | ₹101 cr | −₹88.6 cr | ₹22.6 cr | ₹3.7 cr | ₹154 cr | −₹81.7 cr | −₹99.2 cr | −₹136 cr | −₹8.8 cr | −₹69.4 cr | ₹5.0 cr |
| YoY | — | — | — | +352% | −64% | +52% | — | −539% | −3,801% | −106% | — | — |
| Core profit YoY | — | — | — | — | — | −2% | — | −403% | −382% | −26% | — | — |
| EPS | ₹0.08 | ₹0.77 | −₹0.67 | ₹0.17 | ₹0.03 | ₹1.16 | −₹0.61 | −₹0.75 | −₹1.02 | −₹0.07 | −₹0.52 | ₹0.04 |
| Flags | 1 | · | ✓ | 1 | ✓ | 1 | 1 | 2 | 2 | 2 | ✓ | 1 |
Each quarter is read with the same rules. Balance-sheet and cash checks run on half-year and annual quarters; filing-read checks run where a read exists.
Piramal Pharma Ltd. reported revenue of ₹1,951 cr (+11.6% on the year) and net profit of −₹88.6 cr (— on the year) for April to June 2024.
None of the 5 checks that could run raised a question.
No. FinMinutes reports what was filed and the questions the numbers raise. It does not recommend buying, selling or holding any security.
Numbers as filed with the exchanges, read by rules. Every flag is a question with its source, not an accusation. FinMinutes is a financial data and analytics platform; nothing here is a recommendation to buy, sell or hold any security. How each check works.